查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1190763

酵素聯免疫吸附測定 (ELISA) 市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Enzyme-Linked Immunosorbent Assay (Elisa) Market- Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，酵素聯免疫吸附測定 (ELISA) 市場預計將以 8% 的複合年增長率增長。

COVID-19 增加了全球對 ELISA 等免疫測定的需求。 這主要是由於感染率增加，這增加了對有效診斷的需求。 根據 2020 年 3 月在 NCBI 期刊上發表的題為“Diagnosing COVID-19”的數據，根據“The Disease and Tools for Detection”，SARS-CoV-2 可以通過 ELISA 進行高精度檢測。此外，2021 年 2 月，安捷倫科技公司將推出的“Agilent Dako SARS-CoV -2 IgG 酵素聯免疫吸附測定（ELISA）試劑盒”正在發售。 因此，對具有成本效益的診斷以接受適當治療的需求不斷增加，預計將推動市場增長。

HIV、登革熱、肝炎、瘧疾、流感和其他各種傳染病的發病率不斷上升是市場增長的主要原因。 根據世衛組織 2022 年 7 月更新的數據，到 2020 年底，全球估計有 3770 萬人感染艾滋病毒，其中超過三分之二（2560 萬）生活在非洲地區。 同一份文件還指出，登革熱是世界十大健康威脅之一。 在過去的 50 年裡，全球登革熱的發病率增加了 30 倍。 根據世界衛生組織 2022 年 6 月的更新，全世界有超過 3.54 億人患有乙型或丙型肝炎。 此類感染髮生率的增加增加了對診斷的需求。 越來越多地使用先進的診斷工具，例如用於疾病篩查的酵素聯免疫吸附測定，正在推動市場的增長。

此外，面臨患上各種傳染病和慢性病風險的老齡化人口的增加也在推動市場增長方面發揮著關鍵作用。 NCBI 於 2021 年 7 月更新的數據顯示，與年輕患者相比，潛在的嚴重感染在老年患者中更為常見。 預計這些因素將顯著增加對酵素聯免疫吸附測定市場的需求，從而促進市場增長。

此外，主要市場參與者在酵素聯免疫吸附測定方面的創新也推動了市場增長。 例如，2021 年 9 月，Bio-Rad 推出了 Bio-PlexPro Human IgA and IgM SARS-CoV-2 panel，可檢測針對四種 SARS-CoV-2 抗原的 IgA 和 IgM 抗體。 這種多重免疫檢測組合已幫助疫苗開發人員確定從開發到臨床階段再到上市後研究的治療效果。 同樣在 2021 年 12 月，ArcticZymes Technologies 推出了一種新的 ELISA 免疫測定產品，這是一種必不可少的消費者支持產品，用於在基因治療和病毒疫苗製造的生物製造過程中使用 M-SAN HQ 酵素。 此類產品的推出正在推動市場的增長。

但是，嚴格的許可規定和操作設備的熟練工人短缺限制了市場的增長。

酵素聯免疫吸附測定的市場趨勢

疾病診斷應用領域有望佔據主要市場份額

由於酵素聯免疫吸附試驗在診斷腫瘤抗原方面的應用不斷擴大，疾病診斷領域有望佔據很大份額。 根據 2022 年 2 月發布的世界衛生組織關於癌症的重要事實，全世界每年約有 400,000 名兒童患癌症。 根據 GLOBOCAN 2020 報告，2020 年全球癌症患者總數將達到約 19,292,789 人。 據估計，到 2040 年將增加到 28,887,940 人。 根據2020年5月發表在Nature Scientific報告上的一篇論文，ELISA還可用於檢測前列腺癌抗原和乳腺癌抗原。 因此，全世界癌症患者數量的增加增加了對 ELISA 的需求。 它可以作為測量癌症標誌物和抗原的有效工具。

此外，根據世界衛生組織發布的《2021年全球結核病報告》，預計2020年全球約有987萬人患有結核病。 2022年7月，WHO公佈了《關於HIV的關鍵事實》，到2021年底，全球約有3840萬人感染HIV，僅2021年就有約150萬人新登記，我猜。 因此，越來越多的傳染病患者將增加對早期檢測的需求，預計這將在預測期內進一步推動該領域的增長。

此外，2022 年 9 月，PerkinElmer 的 Oxford Immunotech 宣布美國 FDA 已批准使用 T 細胞選擇試劑盒進行 T 點自動化。 具有成本效益的診斷和抗原檢測的高精度相結合，增加了對 ELISA 的需求並推動了市場的增長。

預計北美將佔據重要的市場份額

目前，北美在酵素聯免疫吸附測定 (ELISA) 市場佔據主導地位，預計在預測期內將繼續如此。 此外，影響該地區的大流行增加了對這些免疫測定的需求。 在北美地區，美國占據了最大的市場份額。

這是由於慢性病、傳染病、老年人口的增加，以及醫療基礎設施的發展和醫療設備的普及。 在美國，癌症是導致住院的主要原因之一。 根據 GLOBOCAN 2020 報告，2020 年美國癌症患者總數將約佔 2,281,658 人。 據估計，到 2040 年將增加到 3,123,452。 根據國家糖尿病統計報告，2020 年美國約有 3730 萬人被發現患有糖尿病，約有 9600 萬成年人被發現處於糖尿病前期。 美國國家腎臟基金會 2020 年的一份報告估計，美國約有 3600 萬成年人患有慢性腎病。 疾病預防控制中心 2020 年的一份報告顯示，大約有 1570 萬美國人患有慢性下呼吸道疾病。 因此，隨著慢性病患病率的增加，對免疫測定的需求不斷增加，推動了市場的發展。

此外，政府機構和製藥公司對慢性病和糖尿病等疾病的高額研發支出也是推動該地區市場的主要因素之一。 例如，根據美國研究和製藥製造商協會的數據，生物製藥行業在 2021 年的研發投資估計將達到 1023 億美元。

因此，上述所有因素預計將在預測期內提振該地區的市場。

酵素聯免疫吸附測定市場的競爭分析

酵素聯免疫吸附測定 (ELISA) 市場分散且競爭激烈，由幾家主要參與者組成。 從市場份額的角度來看，一些主要參與者目前主導著市場。 目前的市場主導者包括 Thermo Fisher Scientific、Abcam PLC、Merck kGaA、Bio-Rad Laboratories, Inc、Cell Biolabs, Inc、Promega Corporation、Zeus Scientific, Inc、Enzo Life Sciences, Inc、Arbor Assays, Inc、Biolegend、Agilent Technologies、公司、J.Mitra&Co.Pvt Ltd 等

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 慢性病和感染的發病率增加
    • 提高人們對早期診斷的認識
  • 市場製約因素
    • 與授權相關的嚴格規定
    • 缺乏熟練操作設備的人員
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 通過方法
    • 直接 ELISA
    • 獨立酵素聯免疫吸附試驗
    • 夾心法
    • 競爭性 ELISA 方法
  • 通過申請
    • 疾病診斷
    • 疫苗開發
    • 其他應用
  • 按地區列出
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Thermo Fisher Scientific
    • Abcam Plc
    • Merck KGaA
    • Bio-Rad Laboratories, Inc
    • Cell Biolabs, Inc
    • Promega Corporation
    • Zeus Scientific, Inc
    • Enzo-lifesciences, Inc
    • Arbor Assays, Inc
    • Biolegend, Inc
    • Agilient Technologies, Inc
    • J. Mitra & Co. Pvt Ltd

第7章 市場機會今後動向

簡介目錄
Product Code: 90441

The enzyme-linked immunosorbent assay (ELISA) market is projected to register a CAGR of 8% during the forecast period.

COVID-19 has increased the demand for immunoassays like ELISA across the globe. This is mainly due to the increase in infection rates, which increased the necessity for effective diagnosis. According to the data published in the NCBI Journal in March 2020 titled "Diagnosing COVID-19: The Disease and Tools for Detection", SARS-CoV-2 can be detected by the ELISA with high accuracy. Moreover, in February 2021, Agilent Technologies Inc. launched the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit to detect immunoglobulin G (IgG) antibodies qualitatively to SARS-CoV-2 in human serum or plasma. Thus, the increasing demand for cost-effective diagnoses to get the appropriate treatment is expected to drive the market's growth.

The increasing incidence of infectious diseases such as HIV, dengue, hepatitis, malaria, influenza, and various other infections is a significant factor contributing to the market's growth. According to the WHO data updated in July 2022, an estimated 37.7 million people were living with HIV globally at the end of 2020, and over two-thirds (25.6 million) of them are in the African region. Also, the same source stated that dengue fever is one of the top ten global health threats. There has been a 30-fold increase in global dengue incidence over the past 50 years. According to World Health Organization updates from June 2022, over 354 million people across the globe live with Hepatitis B or C infections. Such an increasing incidence of infectious diseases increased the demand for diagnosis. The increased usage of advanced diagnostic tools, such as enzyme-linked immunosorbent assays for screening diseases, is attributed to the market's growth.

Furthermore, the increase in the geriatric population at risk of developing various infections and chronic disorders also plays a crucial role in driving the market's growth. as per the data updated by NCBI in July 2021, potentially serious infections are quite common in older patients than in younger ones. Such factors are expected to significantly increase the demand for the enzyme-linked immunosorbent assay market, thereby increasing the market's growth.

Moreover, key market players' innovations in enzyme immunoassays also add to the market growth. For instance, in September 2021, Bio-Rad launched the Bio-PlexPro Human IgA and IgM SARS-CoV-2 panels to detect IgA and IgM antibodies against four SARS-CoV-2 antigens. The multiplex immunoassay panels helped the vaccine developers determine therapeutic efficacy from development through clinical phases and postmarket surveillance studies. Also, in December 2021, ArcticZymes Technologies launched a new ELISA immunoassay product, an essential support product for consumers which used the M-SAN HQ enzyme in biomanufacturing processes for gene therapy and viral vaccine production. Such product launches are boosting market growth.

However, stringent regulations for approval and a lack of skilled personnel handling equipment are restraining the market's growth.

Enzyme-Linked Immunosorbent Assay Market Trends

Disease Diagnosis Application Segment is Expected to Hold a Major Market Share

The disease diagnosis segment is expected to hold a significant share due to the increasing application of enzyme-linked immunosorbent assay tests in diagnosing tumor antigens. According to the World Health Organization's key facts on cancer published in February 2022, around 400,000 children worldwide develop cancer every year. According to the GLOBOCAN 2020 report, the total number of people in the world affected by cancer in 2020 accounts for around 19,292,789 cases. The number is estimated to rise to 28,887,940 cases by 2040. According to the article published in Nature Scientific report in May 2020, ELISA can also be used to detect prostate cancer antigens and breast cancer antigens. This increase in cancer cases across the globe increased the demand for ELISA. It can serve as an effective tool for measuring cancer markers or antigens.

Also, according to the Global Tuberculosis Report 2021 published by the WHO, around 9.87 million people worldwide were estimated to be affected by tuberculosis in 2020. Also, the WHO, in its July 2022 key facts on HIV, estimated that around 38.4 million people worldwide would be affected by HIV by the end of the year 2021, with about 1.5 million new cases being registered in 2021 alone. Thus, the increasing cases of infectious diseases are expected to increase the demand for early detection, which is further expected to boost the segment's growth over the forecast period.

Moreover, in September 2022, PerkinElmer's Oxford Immunotec announced that the US FDA had approved using the T-Cell select reagent kit to automate its T-Spot. Cost-effective diagnosis coupled with the accuracy of detection in antigens increased the demand for ELISA and propelled the market's growth.

North America is Expected to Hold a Significant Share in the Market

Currently, North America dominates the market for enzyme-linked immunosorbent assay and is expected to continue its stronghold during the forecast period. The pandemic affecting the region has also increased the need for these immunoassays. United States holds the largest market share in the North American region.

This can be attributed to the increasing incidence rates of chronic disorders, infectious diseases, and the increasing geriatric population, as well as the well-developed healthcare infrastructure and increasing penetration of medical devices in the region. Cancer is one of the leading causes of hospitalization in United States. According to the GLOBOCAN 2020 report, the total number of people in United States affected by cancer in 2020 accounts for around 2,281,658 cases. The number is estimated to rise to 3,123,452 cases by 2040. According to the National Diabetes Statistics Report, in 2020, about 37.3 million people in United States were found to have diabetes; around 96 million adults were found to have pre-diabetes. ​The National Kidney Foundation 2020 estimated that about 36 million adults in United States have chronic kidney diseases. ​A report by the CDC in 2020 showed that around 15.7 million Americans are affected by chronic lower respiratory diseases. Hence, with the increase in the prevalence of chronic diseases, there is an increasing demand for immunoassays, driving the market.

Moreover, high expenditure on R&D by government organizations and pharmaceutical companies for disorders and diseases, such as chronic ailments and diabetes, are some of the primary factors driving the regional market. For instance, as per Pharmaceutical Research and Manufacturers of America, the biopharmaceutical industry invested an estimated USD 102.3 billion in R&D in 2021.

Thus, all factors above are expected to boost the market in the region over the forecast period.

Enzyme-Linked Immunosorbent Assay Market Competitive Analysis

The enzyme-linked immunosorbent assay (ELISA) market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Thermo Fisher Scientific, Abcam PLC, Merck kGaA, Bio-Rad Laboratories, Inc, Cell Biolabs, Inc, Promega Corporation, Zeus Scientific, Inc, Enzo Life Sciences, Inc, Arbor Assays, Inc, Biolegend, Agilient Technologies, Inc, J. Mitra & Co. Pvt Ltd, and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Chronic and Infectious Diseases
    • 4.2.2 Growing Awareness among People for Early Diagnosis
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations for Approval
    • 4.3.2 Lack of Skilled Personnel for Handling the Equipment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Method
    • 5.1.1 Direct ELISA
    • 5.1.2 Indirect ELISA
    • 5.1.3 Sandwich ELISA
    • 5.1.4 Competitive ELISA
  • 5.2 By Application
    • 5.2.1 Disease diagnosis
    • 5.2.2 Vaccine Development
    • 5.2.3 Other Applications
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Thermo Fisher Scientific
    • 6.1.2 Abcam Plc
    • 6.1.3 Merck KGaA
    • 6.1.4 Bio-Rad Laboratories, Inc
    • 6.1.5 Cell Biolabs, Inc
    • 6.1.6 Promega Corporation
    • 6.1.7 Zeus Scientific, Inc
    • 6.1.8 Enzo-lifesciences, Inc
    • 6.1.9 Arbor Assays, Inc
    • 6.1.10 Biolegend, Inc
    • 6.1.11 Agilient Technologies, Inc
    • 6.1.12 J. Mitra & Co. Pvt Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS